Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report

Abstract

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Fusion‐positive non‐small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications

“…Many other fusions can be exceptionally detected in other genes in NSCLC patients, such as BRAF, EGFR , and FGFR fusions 111–118 . Despite the very low frequency, it may be of strong interest to look for these gene rearrangements, since targeted therapy could be administered to these NSCLC patients.…”

“…All these rare fusions were detected using NGS. Different therapeutic strategies have been proposed for NSCLC patients harboring a BRAF fusion 116,119–121 . Therefore, trametinib or vemurafenib single therapy can induce different responses in these patients 116,119–121 .…”

“…110 Many other fusions can be exceptionally detected in other genes in NSCLC patients, such as BRAF, EGFR, and FGFR fusions. [111][112][113][114][115][116][117][118] Despite the very low frequency, it may be of strong interest to look for these gene rearrangements, since targeted therapy could be administered to these NSCLC patients. BRAF fusions, which represent a totally different mechanism compared to BRAF mutations, can be identified in different solid tumors such as melanoma, astrocytoma, thyroid cancer, colorectal and pancreatic carcinoma, and NS-NSCLC.…”

“…Different therapeutic strategies have been proposed for NSCLC patients harboring a BRAF fusion. 116,[119][120][121] Therefore, trametinib or vemurafenib single therapy can induce different responses in these patients. 116,[119][120][121] It has been reported that an EGFR mutation plus an acquired AGK::BRAF fusion identified in a lung adenocarcinoma was sensitive to MEK inhibitor plus EGFR TKI therapy.…”

“…116,[119][120][121] Therefore, trametinib or vemurafenib single therapy can induce different responses in these patients. 116,[119][120][121] It has been reported that an EGFR mutation plus an acquired AGK::BRAF fusion identified in a lung adenocarcinoma was sensitive to MEK inhibitor plus EGFR TKI therapy. 122 With the rapid progress in improving NGS technology, EGFR fusions have been detected in a few subsets of NSCLC patients, representing between 0.05% and 0.15% of NSCLC.…”